drugset / Trial / NCT01773460

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane

NCT01773460

Phase 3 Terminated 3 enrolled GBG Forschungs GmbH Novartis · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Everolimus will be given to patients with metastatic breast cancer who already has a progress taking Everolimus but with a change in the endocrine treatment.

Timeline

Start
2013-07
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule

Indications